China Resources Medical Holdings Company Limited

DB:1PH Stock Report

Market Cap: €610.4m

China Resources Medical Holdings Valuation

Is 1PH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1PH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1PH (€0.46) is trading below our estimate of fair value (€4.19)

Significantly Below Fair Value: 1PH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1PH?

Key metric: As 1PH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1PH. This is calculated by dividing 1PH's market cap by their current earnings.
What is 1PH's PE Ratio?
PE Ratio15.9x
EarningsCN¥293.95m
Market CapCN¥4.67b

Price to Earnings Ratio vs Peers

How does 1PH's PE Ratio compare to its peers?

The above table shows the PE ratio for 1PH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.6x
RHK RHÖN-KLINIKUM
18.9x7.5%€850.1m
M12 M1 Kliniken
18x17.5%€302.4m
LIK LIMES Schlosskliniken
22.5xn/a€96.2m
JTH Gesundheitswelt Chiemgau
6.8xn/a€23.8m
1PH China Resources Medical Holdings
15.9x31.9%€5.0b

Price-To-Earnings vs Peers: 1PH is good value based on its Price-To-Earnings Ratio (15.9x) compared to the peer average (16.6x).

Price to Earnings Ratio vs Industry

How does 1PH's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1PH 15.9xIndustry Avg. 18.8xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1PH is good value based on its Price-To-Earnings Ratio (15.9x) compared to the European Healthcare industry average (18.5x).

Price to Earnings Ratio vs Fair Ratio

What is 1PH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1PH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.9x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: 1PH is good value based on its Price-To-Earnings Ratio (15.9x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1PH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.46
€0.74
+59.3%
35.8%€1.16€0.38n/a5
Nov ’25€0.46
€0.74
+61.3%
35.8%€1.16€0.38n/a5
Oct ’25€0.50
€0.74
+49.0%
35.8%€1.16€0.38n/a5
Sep ’25€0.37
€0.74
+97.6%
35.8%€1.16€0.38n/a5
Aug ’25€0.34
€0.79
+135.0%
31.4%€1.18€0.43n/a5
Jul ’25€0.38
€0.82
+113.5%
27.1%€1.18€0.53n/a5
Jun ’25€0.45
€0.82
+82.1%
27.1%€1.18€0.53n/a5
May ’25€0.48
€0.73
+51.0%
19.0%€0.89€0.54n/a4
Apr ’25€0.46
€0.75
+64.1%
14.8%€0.89€0.62n/a4
Mar ’25€0.50
€0.88
+77.2%
26.1%€1.25€0.62n/a4
Feb ’25€0.47
€1.02
+115.7%
33.1%€1.55€0.62n/a5
Jan ’25€0.55
€1.02
+87.1%
29.8%€1.54€0.63n/a6
Dec ’24€0.52
€1.02
+98.0%
29.8%€1.54€0.63n/a6
Nov ’24€0.55
€1.05
+90.0%
28.6%€1.56€0.63€0.466
Oct ’24€0.60
€1.05
+75.5%
28.6%€1.57€0.64€0.506
Sep ’24€0.68
€1.03
+53.0%
27.4%€1.53€0.70€0.376
Aug ’24€0.75
€1.01
+34.6%
26.7%€1.52€0.70€0.346
Jul ’24€0.70
€0.97
+37.9%
24.8%€1.37€0.65€0.386
Jun ’24€0.74
€0.99
+34.1%
25.6%€1.41€0.65€0.456
May ’24€0.84
€0.98
+16.6%
28.2%€1.43€0.65€0.485
Apr ’24€0.81
€1.00
+23.8%
28.1%€1.45€0.66€0.465
Mar ’24€0.82
€0.95
+16.5%
34.8%€1.49€0.62€0.505
Feb ’24€0.72
€0.88
+21.0%
35.7%€1.33€0.56€0.475
Jan ’24€0.69
€0.89
+28.3%
42.8%€1.49€0.56€0.555
Dec ’23€0.63
€0.86
+37.0%
41.9%€1.51€0.57€0.526
Nov ’23€0.48
€0.86
+80.3%
42.9%€1.52€0.55€0.556

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

1.0%

1Y

-34.2%

LNA Santé

€234.2m

Engages in the management and operation of health establishments.

2N3

€22.30

7D

-4.9%

1Y

16.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%